We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SR Pharma Completes Name Change to Silence Therapeutics plc
News

SR Pharma Completes Name Change to Silence Therapeutics plc

SR Pharma Completes Name Change to Silence Therapeutics plc
News

SR Pharma Completes Name Change to Silence Therapeutics plc

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SR Pharma Completes Name Change to Silence Therapeutics plc"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Silence Therapeutics plc has announced that the Company's name change from SR Pharma plc has been completed.

The new company name, Silence Therapeutics, and corporate identity have been put in place to reflect the Company’s core focus on RNAi, a therapeutic approach which seeks to ‘silence’ disease relevant genes.

Silence Therapeutics is developing a broad pipeline of RNAi therapeutics based on its proprietary AtuRNAi molecules and systemic delivery system, AtuPLEX.

Silence Therapeutics’ in-house RNAi therapeutic programmes, which are in late-stage pre-clinical development, are focused on systemic cancer indications such as gastro-intestinal and non-small lung cancer.

In addition, Silence Therapeutics has AtuRNAi molecules in clinical development via its collaborators Quark Biotech and its sublicensee Pfizer.

The Company is now trading under the ticker SLN on the AiM market.

Advertisement